Renal cell carcinoma - sunitinib
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Summary
Sunitinib is recommended as a possible first drug treatment for people with advanced and/or metastatic renal cell carcinoma if: immunotherapy (for example, interferon alfa) would be suitable for them and they are mobile and can do light housework or office work. When assessing people with d ...
NICE has been appraising the use of bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma. Following the independent advisory Committee meeting on 14 January 2009 NICE has decided to split this appraisal in two in order to get guidance out to the NHS as quickly as possible.
NICE is also appraising the use of bevacizumab, sorafenib and temsirolimus for first-line treatment options for advanced and/or metastatic renal cell carcinoma and the two drugs also licensed for second-line treatment of advanced or metastatic renal cell carcinoma, sorafenib and sunitinib, guidance is expected to be published later this year.
Guidance documents
Implementing this guidance
Other information
We will consult on our review plans for this guidance in February 2011
About this guidance
Technology appraisals TA169
Issued: March 2009
How this guidance was produced